Repligen (RGEN) Tops Q2 EPS by 9c ; Offers Guidance
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $166.59 +0.54%
Financial Fact:
(Loss) income from operations: 3.75M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
(Loss) income from operations: 3.75M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q2 EPS of $0.54, $0.09 better than the analyst estimate of $0.45. Revenue for the quarter came in at $204 million versus the consensus estimate of $201.47 million.
Outlook:-
FY 2026 EPS between $2.03-$2.09 vs consensus $2.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
- MongoDB (MDB) PT Raised at RBC Capital; 'Shares represent an attractive buying opportunity'
- UBS Reiterates Buy Rating on Sysco (SYY) Following Trip to Company Headquarters
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
